Literature DB >> 577884

[Exchange of aromatically bound halogen for OH- and SCH3-groups in metabolising clozapine in the human organism (author's transl)].

B Stock, G Spiteller, R Heipertz.   

Abstract

8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo-(b,e)(1,4)-diazepine (clozapine, 1) is metabolized in humans by exchange of the aromatic halogen for a hydroxy- or a methylthio-group (compounds 2 and 3). Further metabolites are the N-demethyl derivatives of 2 and 3, the compounds 4 and 5. In addition a clozapine metabolite with the structure 6 with an oxidized piperazine ring was found. The presence of a metabolite with an oxidized sulfur atom is suggested. Possible ways for the formation of these metabolites are discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 577884

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  9 in total

1.  Multiple-dose pharmacokinetics of clozapine in patients.

Authors:  M G Choc; R G Lehr; F Hsuan; G Honigfeld; H T Smith; R Borison; J Volavka
Journal:  Pharm Res       Date:  1987-10       Impact factor: 4.200

2.  Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection.

Authors:  U Bondesson; L H Lindström
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 3.  Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring.

Authors:  A E Balant-Gorgia; L Balant
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

4.  Cytochrome P4502D6 genotype does not determine response to clozapine.

Authors:  M J Arranz; E Dawson; S Shaikh; P Sham; T Sharma; K Aitchison; M A Crocq; M Gill; R Kerwin; D A Collier
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

5.  Serum concentrations of clozapine determined by nitrogen selective gas chromatography.

Authors:  R Heipertz; H Pilz; W Beckers
Journal:  Arch Toxicol       Date:  1977-08-09       Impact factor: 5.153

6.  CSF and serum concentrations of clozapine and its demethyl metabolite: a pilot study.

Authors:  C Nordin; B Almé; U Bondesson
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

Review 7.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Authors:  A Fitton; R C Heel
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

8.  Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance.

Authors:  G Schaber; I Stevens; H J Gaertner; K Dietz; U Breyer-Pfaff
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

9.  Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms.

Authors:  M L Dahl; A Llerena; U Bondesson; L Lindström; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.